Long-Term, Observational, Registry of Patients with Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
This is a registry study that focuses on patients with Myasthenia Gravis (MG) who have used complement inhibitors. Soliris is an example of this type of medication. The purpose of the study is to determine how effectively complement inhibitors treat generalized MG over an extended period of time, as well as how safe complement inhibitors are. The study plans to enroll 500 patients and collect data for up to 5 years.
All study information will be collected as part of your normal medical care with your neurology physician. You will be asked about medical history, ethnicity, race, MG symptoms, treatments and quality of life as part of your regular appointments.
Principal Investigator: Suraj Ashok Muley, MD